June 15, 2021
Akoya to Help Support Leading Philanthropic Organization with Spatial Phenotyping Capabilities
CODEX’s single-cell, multiplex imaging capabilities to be included in Chan Zuckerberg Initiative grantee toolkit to help fuel the next wave of biological discoveries MARLBOROUGH, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company ® , today...

Continue Reading
June 10, 2021
Akoya Announces Publication of New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy and Pathology
Investigators at Johns Hopkins University (JHU) used AstroPath to identify and validate biomarkers for accurate prediction of long-term response to immune checkpoint inhibitors in advanced melanoma AstroPath combines JHU’s famed 3D sky mapping algorithms for managing astronomical-scale datasets...

Continue Reading
June 9, 2021
Akoya Set to Join Russell 3000® Index
MARLBOROUGH, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, is set to join the broad-market Russell 3000 ®  Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on...

Continue Reading
June 4, 2021
Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology
Partnership aims to leverage spatial biology data, generated on Akoya’s Phenoptics™ platform, to inform and guide drug development programs MARLBOROUGH, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company ® , today announced a collaboration...

Continue Reading
June 2, 2021
Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications
Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials MARLBOROUGH, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company ® , today...

Continue Reading
May 18, 2021
Akoya Reports First Quarter 2021 Financial Results and Issues Full Year 2021 Guidance
MARLBOROUGH, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2021. First Quarter Financial Highlights: Total revenue for the first quarter of 2021 was...

Continue Reading
May 17, 2021
Akoya and ZEISS to Co-Market Innovative CODEX® Spatial Biology Workflow
The partnership brings together one of the world’s premier microscopy vendors and Akoya’s high-parameter CODEX® System for advancing the emerging field of spatial phenotyping and discovery MARLBOROUGH, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial...

Continue Reading
May 12, 2021
Akoya to Report First Quarter 2021 Financial Results on May 18, 2021
MARLBOROUGH, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021....

Continue Reading
May 11, 2021
Akoya Biosciences Begins Accepting Applications for First-of-its-Kind Imaging Innovators (I²) Network
Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system’s open, accessible interface MARLBOROUGH, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that its...

Continue Reading
April 20, 2021
Akoya Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MARLBOROUGH, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced the closing of its initial public offering of 7,567,000 shares of its common stock, including the exercise in full by the underwriters of their...

Continue Reading
Displaying 1 - 10 of 15

Search Investor Relations